All In Biotech

Drug Trial Radar · NCT07553429

A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated

A First-in-human, Open-label (Part 1), Randomized (Part 2), Phase I/IIa Trial to Study Safety and Tolerability of Multiple Rising Intravitreal Doses of BI 3812465 in Patients With Center-involved Diabetic Macular Edema

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

49

Planned (sponsor's estimate)

Start

May 14, 2026

Primary completion

Mar 23, 2027

Study completion Jul 6, 2027

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Apr 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with diabetic macular edema that involves the center of the eye. The purpose of this study is to find out how well different doses of a medicine called BI 3812465 are tolerated by people with this condition. This is the first time BI 3812465 is given to humans. This study has 2 parts. In Part 1, a small number of participants receive low, medium, or high doses of BI 3812465. The first participants to start the study get low doses of BI 3812465. Participants who start later get higher doses only if the lower doses were tolerated. In Part 2, a larger number of participants are placed into low, medium, or high dose groups. Participants in both parts of the study get BI 3812465 as injections into the back of the eye for a total of 3 eye injections. Participants are in the study for up to 7 months. During this time, they visit the study site 19 times. Where possible, some visits can be done at the participant's home instead of the study site. At study visits, the doctors check the severity of participants' eye condition and note any health problems that could have been caused by BI 3812465.

Conditions

  • Diabetic Macular Edema

Interventions

  • Low dose BI 3812465Biological

    BI 3812465

  • Medium dose BI 3812465Biological

    BI 3812465

  • High dose BI 3812465Biological

    BI 3812465

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Occurrence of dose limiting events (DLEs) from first investigational medicine product (IMP) administration until end of study (EOS)Time frame: Up to 169 days.
  2. Part 2: Occurrence of ocular adverse events (AEs) in the study eye from first IMP administration until EOSTime frame: Up to 169 days.

Locations

29 sites in 2 countries. Site status is shown where the registry gives one.

  • Associated Retina Consultants, Ltd.

    Phoenix, Arizona · Recruiting

  • Research Network Arizona

    Scottsdale, Arizona · Recruiting

  • Win Retina

    Arcadia, California · Recruiting

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California · Recruiting

  • Global Research Management

    Glendale, California · Recruiting

  • Retina Associates of Southern California

    Huntington Beach, California · Recruiting

  • California Retina Consultants-Oxnard-70187

    Oxnard, California · Recruiting

  • Retinal Consultants Medical Group

    Sacramento, California · Recruiting

  • Bay Area Retina Associates - Walnut Creek

    Walnut Creek, California · Recruiting

  • Retina Group of New England, PC

    Waterford, Connecticut · Recruiting

  • Retina Group of Florida - Fort Myers Retina Center

    Fort Myers, Florida · Recruiting

  • Florida Retina Consultants

    Lakeland, Florida · Recruiting

  • East Florida Eye Institute

    Stuart, Florida · Recruiting

  • Ophthalmic Consultants of Long Island

    Oceanside, New York · Recruiting

  • North Carolina Retina Associates

    Wake Forest, North Carolina · Recruiting

  • Red River Research Partners, LLC

    Fargo, North Dakota · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Not yet recruiting

  • Verum Research, LLC

    Eugene, Oregon · Recruiting

  • EyeHealth Northwest

    Portland, Oregon · Recruiting

  • Tennessee Retina

    Nashville, Tennessee · Recruiting

  • Austin Clinical Research, LLC

    Austin, Texas · Recruiting

  • Retina Consultants of Texas-Bellaire-67493

    Bellaire, Texas · Recruiting

  • Valley Retina Institute, PA

    McAllen, Texas · Recruiting

  • Medical Center Ophthalmology Associates

    San Antonio, Texas · Recruiting

  • Retina Consultants of Texas

    San Antonio, Texas · Recruiting

  • Retina Consultants of Texas-The Woodlands-67575

    The Woodlands, Texas · Recruiting

  • Strategic Clinical Research Group

    Willow Park, Texas · Recruiting

  • Emerson Clinical Research Institute

    Falls Church, Virginia · Recruiting

  • Emanuelli Research & Development Center

    Arecibo, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.